StockData
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp (ABUS) stock

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.11+0.06 (+1.48%)

Close on Nov 18, 2026Market cap $813.16MP/E 5.3Yield –

Arbutus Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Arbutus Biopharma's free cash flow for the twelve months ending Dec 31, 2025 was -$39.64M. For fiscal 2025 it was -$39.64M. The highest annual figure on record is $32.89M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.64M–
FY2024Dec 31, 2024-$65.03M–
FY2023Dec 31, 2023-$86.94M–
FY2022Dec 31, 2022-$35.87M–
FY2021Dec 31, 2021-$68.34M–
FY2020Dec 31, 2020-$51.67M–
FY2019Dec 31, 2019-$71.60M–
FY2018Dec 31, 2018-$69.00M–
FY2017Dec 31, 2017-$55.90M–
FY2016Dec 31, 2016-$61.88M–
FY2015Dec 31, 2015-$58.67M–
FY2014Dec 31, 2014-$13.48M–
FY2013Dec 31, 2013-$7.46M-122.7%
FY2012Dec 31, 2012$32.89M–
FY2011Dec 31, 2011-$7.89M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$4.68M–
Q3 FY2025Sep 30, 2025-$5.82M–
Q2 FY2025Jun 30, 2025-$15.75M–
Q1 FY2025Mar 31, 2025-$13.39M–
Q4 FY2024Dec 31, 2024-$10.40M–
Q3 FY2024Sep 30, 2024-$20.74M–
Q2 FY2024Jun 30, 2024-$14.51M–
Q1 FY2024Mar 31, 2024-$19.39M–
Q4 FY2023Dec 31, 2023-$17.29M–
Q3 FY2023Sep 30, 2023-$21.82M–
Q2 FY2023Jun 30, 2023-$20.42M–
Q1 FY2023Mar 31, 2023-$27.42M-233.5%
Q4 FY2022Dec 31, 2022-$17.12M–
Q3 FY2022Sep 30, 2022-$18.78M–
Q2 FY2022Jun 30, 2022-$20.51M–
Q1 FY2022Mar 31, 2022$20.54M–
Q4 FY2021Dec 31, 2021-$19.66M–
Q3 FY2021Sep 30, 2021-$16.06M–
Q2 FY2021Jun 30, 2021-$14.64M–
Q1 FY2021Mar 31, 2021-$17.98M–
Q4 FY2020Dec 31, 2020-$15.17M–
Q3 FY2020Sep 30, 2020-$12.19M–
Q2 FY2020Jun 30, 2020-$8.87M–
Q1 FY2020Mar 31, 2020-$15.45M–
Q4 FY2019Dec 31, 2019-$13.41M–
Q3 FY2019Sep 30, 2019-$23.73M–
Q2 FY2019Jun 30, 2019-$17.85M–
Q1 FY2019Mar 31, 2019-$16.61M–
Q4 FY2018Dec 31, 2018-$17.30M–
Q3 FY2018Sep 30, 2018-$13.44M–
Q2 FY2018Jun 30, 2018-$18.05M–
Q1 FY2018Mar 31, 2018-$20.22M–
Q4 FY2017Dec 31, 2017-$10.53M–
Q3 FY2017Sep 30, 2017-$16.22M–
Q2 FY2017Jun 30, 2017-$8.20M–
Q1 FY2017Mar 31, 2017-$20.96M–
Q4 FY2016Dec 31, 2016-$17.42M–
Q3 FY2016Sep 30, 2016-$14.88M–

More Arbutus Biopharma figures

See a number that looks wrong?